UA80418C2 - Methods of inducing ovulation using phosphodiesterase inhibitor as non-polypeptide camp level modulator.and method of collecting oocytes for in vitro fertilization - Google Patents

Methods of inducing ovulation using phosphodiesterase inhibitor as non-polypeptide camp level modulator.and method of collecting oocytes for in vitro fertilization Download PDF

Info

Publication number: UA80418C2
Authority: UA; Ukraine
Prior art keywords: ovulation; inhibitor; camp; compound; follicles
Prior art date: 2001-12-14

Application number

UA20040705737A

Other languages

English (en)

Ukrainian (uk)

Inventor

Mark Tepper

Original Assignee

Applied Research Systems

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-12-14

Filing date

2001-12-14

Publication date

2007-09-25

2001-12-14 Application filed by Applied Research Systems filed Critical Applied Research Systems

2007-09-25 Publication of UA80418C2 publication Critical patent/UA80418C2/uk

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pregnancy & Childbirth (AREA)
Gynecology & Obstetrics (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Enzymes And Modification Thereof (AREA)

UA20040705737A 2001-12-14 2001-12-14 Methods of inducing ovulation using phosphodiesterase inhibitor as non-polypeptide camp level modulator.and method of collecting oocytes for in vitro fertilization UA80418C2 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/EP2001/014730 WO2003051344A1 (en)	2001-12-14	2001-12-14	Methods of inducing ovulation_using a non-polypeptide camp level modulator

Publications (1)

Publication Number	Publication Date
UA80418C2 true UA80418C2 (en)	2007-09-25

Family

ID=8164724

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA20040705737A UA80418C2 (en)	2001-12-14	2001-12-14	Methods of inducing ovulation using phosphodiesterase inhibitor as non-polypeptide camp level modulator.and method of collecting oocytes for in vitro fertilization

Country Status (18)

Country	Link
US (1)	US7507707B2 (de)
EP (2)	EP1463493B1 (de)
JP (1)	JP4532115B2 (de)
KR (2)	KR20040075004A (de)
CN (1)	CN1582146A (de)
AT (2)	ATE526013T1 (de)
AU (1)	AU2002217111B2 (de)
BR (2)	BR0117198A (de)
CA (1)	CA2469939C (de)
DE (1)	DE60130813T2 (de)
DK (2)	DK1463493T3 (de)
EA (1)	EA011213B1 (de)
ES (1)	ES2293965T3 (de)
IL (3)	IL162506A0 (de)
MX (1)	MXPA04005782A (de)
PT (2)	PT1463493E (de)
UA (1)	UA80418C2 (de)
WO (1)	WO2003051344A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6861422B2 (en) *	2003-02-26	2005-03-01	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
WO2004087211A2 (en) *	2003-04-01	2004-10-14	Applied Research Systems Ars Holding N.V.	Inhibitors of phosphodiesterases in infertility
DE102004002557A1 (de) *	2004-01-17	2005-08-04	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verwendung von substituierten Pyrimido(5,4-d)pyrimidinen zur Behandlung von Atemwegserkrankungen
WO2005067935A1 (de) *	2004-01-17	2005-07-28	Boehringer Ingelheim International Gmbh	Verwendung von substituierten pteridinen zur behandlung von atemwegserkrankungen
DE102004029784A1 (de) *	2004-06-21	2006-01-05	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) *	2004-07-09	2006-02-02	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
US20060074088A1 (en) *	2004-08-14	2006-04-06	Boehringer Ingelheim International Gmbh	Dihydropteridinones for the treatment of cancer diseases
US7728134B2 (en) *	2004-08-14	2010-06-01	Boehringer Ingelheim International Gmbh	Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060058311A1 (en) *	2004-08-14	2006-03-16	Boehringer Ingelheim International Gmbh	Combinations for the treatment of diseases involving cell proliferation
US7759485B2 (en) *	2004-08-14	2010-07-20	Boehringer Ingelheim International Gmbh	Process for the manufacture of dihydropteridinones
US20060035903A1 (en) *	2004-08-14	2006-02-16	Boehringer Ingelheim International Gmbh	Storage stable perfusion solution for dihydropteridinones
EP1630163A1 (de) *	2004-08-25	2006-03-01	Boehringer Ingelheim Pharma GmbH & Co.KG	Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1632493A1 (de) *	2004-08-25	2006-03-08	Boehringer Ingelheim Pharma GmbH & Co.KG	Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE102004058337A1 (de) *	2004-12-02	2006-06-14	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
EP1915155A1 (de) *	2005-08-03	2008-04-30	Boehringer Ingelheim International GmbH	Dihydropteridinone bei der behandlung von atemwegserkrankungen
US7439358B2 (en) *	2006-02-08	2008-10-21	Boehringer Ingelheim International Gmbh	Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
EP3098223A1 (de) *	2007-08-03	2016-11-30	Boehringer Ingelheim International GmbH	Kristalline form eines dihydropteridionderivats
US8546566B2 (en)	2010-10-12	2013-10-01	Boehringer Ingelheim International Gmbh	Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en)	2010-11-29	2016-06-07	Boehringer Ingelheim International Gmbh	Method for treating acute myeloid leukemia
US9370535B2 (en)	2011-05-17	2016-06-21	Boehringer Ingelheim International Gmbh	Method for treatment of advanced solid tumors
CN103169699B (zh) *	2011-12-22	2014-11-12	中国农业大学	来曲唑在用于制备成年牛超数排卵药物中的应用
WO2014089913A1 (zh) *	2012-12-12	2014-06-19	山东亨利医药科技有限责任公司	作为酪氨酸激酶抑制剂的并环化合物
JP2016525532A (ja)	2013-07-26	2016-08-25	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	骨髄異形成症候群の処置
US9867831B2 (en)	2014-10-01	2018-01-16	Boehringer Ingelheim International Gmbh	Combination treatment of acute myeloid leukemia and myelodysplastic syndrome

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5087615A (en)	1989-03-17	1992-02-11	Applied Research Systems Ars Holding N.V.	Novel method of ovulation induction in humans
US5710170A (en)	1995-12-15	1998-01-20	Merck Frosst Canada, Inc.	Tri-aryl ethane derivatives as PDE IV inhibitors
GB9603723D0 (en)	1996-02-22	1996-04-24	Merck & Co Inc	Diphenyl pyridyl derivatives as pde iv inhibitors
AP2001002304A0 (en)	1996-05-03	2001-12-31	Pfizer	Substituted indazole derivatives and related compounds
CA2252537A1 (en)	1996-05-20	1997-11-27	Darwin Discovery Limited	Benzofuran carboxamides and their therapeutic use
DE69738949D1 (de)	1996-05-20	2008-10-09	Darwin Discovery Ltd	Chinolincarboxamide als tnf-inhibitoren und als pde-iv inhibitoren
CA2252501A1 (en)	1996-05-20	1997-11-27	Darwin Discovery Limited	Quinoline sulfonamides as tnf inhibitors and as pde-iv inhibitors
EP0934307B1 (de)	1996-06-19	2011-04-27	Aventis Pharma Limited	Substituierte azabicyclische verbindungen und ihre verwendung als inhibitoren des tnf und der cyclischen amp phosphodiestrase
CN1080260C (zh)	1996-06-25	2002-03-06	美国辉瑞有限公司	取代的吲哚衍生物以及它们作为iv型磷酸二酯酶(pde)和肿瘤坏死因子(tnf)抑制剂的用途
GB9614718D0 (en)	1996-07-12	1996-09-04	Bayer Ag	3-ureido-pyridofurans and -pyridothiophenes
TR199900732T2 (xx)	1996-10-02	1999-08-23	Janssen Pharmaceutica N.V.	PDE IV inhibe eden 2-siyanoiminoimidazol t�revleri.
GB9622386D0 (en)	1996-10-28	1997-01-08	Sandoz Ltd	Organic compounds
EP0946541B1 (de)	1996-11-06	2003-07-30	Darwin Discovery Limited	Chinoline und deren therapeutische verwendung
JP3237109B2 (ja) *	1996-12-13	2001-12-10	田辺製薬株式会社	医薬組成物
US6472425B1 (en) *	1997-10-31	2002-10-29	Nitromed, Inc.	Methods for treating female sexual dysfunctions
HU228736B1 (en) *	1998-04-23	2013-05-28	Zentaris Ivf Gmbh	Use of lhrh atnagonists in the production of pharmaceutical compostion for the treatment of fertility disorders
KR20010043828A (ko) *	1998-05-26	2001-05-25	에바-마리아 시마-메이어, 얼설라 멜져, 마거, 하르트만	ｃＡＭＰ-증강 화합물 단독 또는 감수분열-자극 화합물하나 이상과의 조합에 의한 불임 치료 방법
IL140070A (en)	1998-06-10	2004-06-20	Altana Pharma Ag	History of benzamide and pharmaceutical preparations containing them
US6316472B1 (en)	1999-05-13	2001-11-13	Merck Frosst Canada & Co.	Heterosubstituted pyridine derivatives as PDE 4 inhibitors
SK287231B6 (sk) *	1999-08-21	2010-04-07	Nycomed Gmbh	Liečivo zahŕňajúce PDE inhibítor a agonistu beta2 adrenoreceptora
US6258833B1 (en) *	1999-12-23	2001-07-10	Icos Corporation	Cyclic AMP-specific phosphodiesterase inhibitors
US20030187056A1 (en) *	2000-04-17	2003-10-02	Terry Bernard Robert	Live cell procedures to identify to identify compounds modulating intracellular distribution of phosphodiesterase( pde) enzymes
AU2001264694B8 (en)	2000-05-19	2006-05-04	Laboratoires Serono Sa	Use of pyrazole derivatives for treating infertility
EP1289557B1 (de) *	2000-06-06	2006-07-12	Glaxo Group Limited	Krebsbehandlung zusammensetzung, welche ein antineoplastisches mittel und pde4 inhibitor enthält
US20020065324A1 (en)	2000-08-11	2002-05-30	Stephen Palmer	Methods of inducing ovulation
US6953774B2 (en) *	2000-08-11	2005-10-11	Applied Research Systems Ars Holding N.V.	Methods of inducing ovulation
WO2004087211A2 (en) *	2003-04-01	2004-10-14	Applied Research Systems Ars Holding N.V.	Inhibitors of phosphodiesterases in infertility

2001
- 2001-12-14 DK DK01274987T patent/DK1463493T3/da active
- 2001-12-14 MX MXPA04005782A patent/MXPA04005782A/es active IP Right Grant
- 2001-12-14 KR KR10-2004-7009259A patent/KR20040075004A/ko not_active Ceased
- 2001-12-14 CA CA2469939A patent/CA2469939C/en not_active Expired - Fee Related
- 2001-12-14 KR KR1020097000508A patent/KR101056916B1/ko not_active Expired - Fee Related
- 2001-12-14 PT PT01274987T patent/PT1463493E/pt unknown
- 2001-12-14 EP EP01274987A patent/EP1463493B1/de not_active Expired - Lifetime
- 2001-12-14 BR BR0117198-4A patent/BR0117198A/pt not_active IP Right Cessation
- 2001-12-14 AU AU2002217111A patent/AU2002217111B2/en not_active Ceased
- 2001-12-14 EA EA200400808A patent/EA011213B1/ru not_active IP Right Cessation
- 2001-12-14 AT AT07018904T patent/ATE526013T1/de active
- 2001-12-14 BR BRPI0117198-4A patent/BRPI0117198B1/pt unknown
- 2001-12-14 IL IL16250601A patent/IL162506A0/xx unknown
- 2001-12-14 WO PCT/EP2001/014730 patent/WO2003051344A1/en not_active Ceased
- 2001-12-14 JP JP2003552277A patent/JP4532115B2/ja not_active Expired - Fee Related
- 2001-12-14 UA UA20040705737A patent/UA80418C2/uk unknown
- 2001-12-14 ES ES01274987T patent/ES2293965T3/es not_active Expired - Lifetime
- 2001-12-14 DK DK07018904.8T patent/DK1908463T3/da active
- 2001-12-14 AT AT01274987T patent/ATE374606T1/de active
- 2001-12-14 CN CNA01823951XA patent/CN1582146A/zh active Pending
- 2001-12-14 PT PT07018904T patent/PT1908463E/pt unknown
- 2001-12-14 US US10/498,639 patent/US7507707B2/en not_active Expired - Fee Related
- 2001-12-14 DE DE60130813T patent/DE60130813T2/de not_active Expired - Lifetime
- 2001-12-14 EP EP07018904A patent/EP1908463B1/de not_active Expired - Lifetime
2004
- 2004-06-14 IL IL162506A patent/IL162506A/en not_active IP Right Cessation
2010
- 2010-04-15 IL IL205106A patent/IL205106A/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
DK1908463T3 (da)	2011-11-28
PT1908463E (pt)	2011-12-19
CN1582146A (zh)	2005-02-16
EA200400808A1 (ru)	2004-12-30
WO2003051344A1 (en)	2003-06-26
DE60130813D1 (de)	2007-11-15
DK1463493T3 (da)	2008-02-04
EP1463493B1 (de)	2007-10-03
IL162506A0 (en)	2005-11-20
DE60130813T2 (de)	2008-07-03
KR20090009336A (ko)	2009-01-22
EP1908463B1 (de)	2011-09-28
US20050148501A1 (en)	2005-07-07
AU2002217111B2 (en)	2007-05-31
KR20040075004A (ko)	2004-08-26
PT1463493E (pt)	2008-01-04
IL205106A0 (en)	2010-11-30
EP1463493A1 (de)	2004-10-06
EP1908463A3 (de)	2009-11-25
CA2469939A1 (en)	2003-06-26
KR101056916B1 (ko)	2011-08-12
JP4532115B2 (ja)	2010-08-25
ATE526013T1 (de)	2011-10-15
BR0117198A (pt)	2004-10-26
AU2002217111A1 (en)	2003-06-30
BRPI0117198B1 (pt)	2018-03-13
MXPA04005782A (es)	2004-09-13
AU2002217111B8 (en)	2003-06-30
US7507707B2 (en)	2009-03-24
IL205106A (en)	2013-02-28
ES2293965T3 (es)	2008-04-01
EP1908463A2 (de)	2008-04-09
IL162506A (en)	2012-03-29
CA2469939C (en)	2012-06-19
EA011213B1 (ru)	2009-02-27
ATE374606T1 (de)	2007-10-15
JP2005516924A (ja)	2005-06-09

Publication	Publication Date	Title
UA80418C2 (en)	2007-09-25	Methods of inducing ovulation using phosphodiesterase inhibitor as non-polypeptide camp level modulator.and method of collecting oocytes for in vitro fertilization
Hughes et al.	1996	Estrogen promotes apoptosis of murine osteoclasts mediated by TGF–β
Frump et al.	2015	Estradiol improves right ventricular function in rats with severe angioproliferative pulmonary hypertension: effects of endogenous and exogenous sex hormones
Krishna et al.	1989	Histamine, mast cells and ovarian function
US7803760B2 (en)	2010-09-28	Methods of inducing ovulation
MXPA05010373A (es)	2005-12-05	Inhibidores de fosfodiesterasas en infertilidad.
Mondragón et al.	2016	Effect of restricted suckling on the onset of follicular dynamics and body condition score in Brahman cattle raised under tropical conditions
EP0723453B1 (de)	2000-03-15	Methode zur behandlung von reproduktionserkrankungen
Kann et al.	1999	Demonstration of in vivo mammogenic and lactogenic effects of recombinant ovine placental lactogen and mammogenic effect of recombinant ovine GH in ewes during artificial induction of lactation
HRP20040070A2 (en)	2004-10-31	Use of lh in controlled ovarian hyperstimulation
US20010053762A1 (en)	2001-12-20	Method of treating reproductive disorders
PT1381431E (pt)	2007-07-03	Inibição da aromatase para melhorar a reprodução assistida.
US20020065324A1 (en)	2002-05-30	Methods of inducing ovulation
SK14242003A3 (sk)	2004-03-02	Použitie inhibítora aromatázy, farmaceutický prostriedok s obsahom inhibítora aromatázy a farmaceutické balenie
US9248142B2 (en)	2016-02-02	Non-hormonal female contraceptive
ES2375646T3 (es)	2012-03-02	MÉTODOS DE INDUCIR LA OVULACIÓN UTILIZANDO UN MODULADOR NO POLIPEPT�?DICO DE LOS NIVELES DE cAMP.
CA3228691A1 (en)	2023-03-02	Methods for reproductive management of sheep and goats
Owen	1993	Growth hormone co-treatment in superovulation programmes
Sterrenburg et al.	2009	Drugs in reproductive medicine
Suvisaari	2000	7 α-Methyl-19-Nortestosterone (MENT): Pharmacokinetics and Antigonadotropic Effects in Men
CN102204898A (zh)	2011-10-05	用非多肽环一磷酸腺苷水平调节剂诱导排卵的方法
EP2417971A1 (de)	2012-02-15	Clomiphene zur Verwendung zur Erhöhung der Chancen auf eine Schwangerschaft bei Frauen mit verminderter Ovarialreserve